Click Therapeutics, Inc., a leader in Digital Therapeutics™ as prescription medical treatments, announced plans to accelerate its development initiatives in obesity and cardiometabolic disease...
Otsuka Pharmaceutical, Co. Ltd. and Click Therapeutics, Inc., announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn™ (developed as CT-152), the...